CCEP Delivers Strong H1 2026 and Reaffirms Full-Year Guidance
CCEP sits 23% above its 52-week low of $84.655.
Summary
H1 2026 revenue reached €10.72 billion, up 4.4%, with comparable diluted EPS of €2.20, up 10.6% FXN. Full-year guidance was reaffirmed, and the €1 billion buyback remains on track.
Key Events · Earnings and Guidance · CCEP
-
H1 Revenue and Profit Growth
Revenue reached €10.72 billion, up 4.4% reported and 6.1% FXN. Comparable diluted EPS grew 10.6% FXN to €2.20, driven by volume growth of 2.2% and disciplined cost management.
-
FY26 Guidance Reaffirmed
Management reiterated full-year targets: revenue growth of 3-4%, operating profit growth of ~7%, and comparable free cash flow of at least €1.7 billion, despite geopolitical headwinds.
-
Share Buyback Progress
€593 million of the €1 billion buyback program completed as of 31 July 2026, with the remainder expected over the course of the year.
-
Interim Dividend Declared
An interim dividend of €0.82 per share was declared, calculated as 40% of the prior year's full-year dividend, and paid in May 2026.
Analysis · CCEP · Manufacturing
A solid first half saw revenue climb 4.4% to €10.72 billion, while comparable diluted EPS advanced 10.6% on an FX-neutral basis. Volume expanded 2.2% despite a challenging consumer backdrop, fueled by innovation in zero sugar, energy, and sports drinks. The company reaffirmed its full-year outlook—including at least €1.7 billion in comparable free cash flow and a €1 billion buyback, of which €593 million is already complete. Although geopolitical risks from the Middle East add uncertainty, the results underscore resilience and disciplined execution, supporting the investment thesis.
At the time of this filing, CCEP was trading at $104.12 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $48B. The 52-week trading range was $84.66 to $113.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.